Nevirapine overdosage

Revision as of 03:59, 10 January 2014 by ShiSheng (talk | contribs) (Created page with "__NOTOC__ {{Nevirapine}} {{CMG}}; {{AE}} {{SS}} ==Overdosage== There is no known antidote for nevirapine overdosage. Cases of immediate-release VIRAMUNE overdose at doses ran...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Nevirapine
VIRAMUNE® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Overdosage

There is no known antidote for nevirapine overdosage. Cases of immediate-release VIRAMUNE overdose at doses ranging from 800 to 1800 mg per day for up to 15 days have been reported. Patients have experienced events including edema, erythema nodosum, fatigue, fever, headache, insomnia, nausea, pulmonary infiltrates, rash, vertigo, vomiting and weight decrease. All events subsided following discontinuation of immediate-release VIRAMUNE.[1]

References

  1. "VIRAMUNE (NEVIRAPINE) TABLET, EXTENDED RELEASE [BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.]". Retrieved 10 January 2014.

Adapted from the FDA Package Insert.